| | Population (CT n = 327, HPV n = 324) | Vaccinees (CT n = 248, HPV n = 245) | Non vaccinees (CT n = 77, HPV n = 77) | p-value |
|---|
n | pr | sd | n | pr | sd | n | pr | sd |
|---|
CT | 15 | 4.6 | 1.2 | 10 | 4.0 | 1.3 | 5 | 6.5 | 2.8 | 0.360 |
HPV global | 95a | 29.5 | 2.5 | 70 | 28.6 | 2.9 | 25 | 32.5 | 5.4 | 0.567 |
HPV vaccine | 9b | 2.8 | 0.9 | 6 | 2.4 | 1.0 | 3 | 3.9 | 2.2 | 0.451 |
- Of 327 samples analysed, 327 were informative for Chlamydia trachomatis (CT) and 324 for Human papillomaviruses (HPV)
- Two subjects were non informative regarding their vaccine status. They were CT and HPV negative. The 15 CT positive cases were found in 13 HPV positive cases and 2 HPV negative cases
- n: number of positive subjects; pr: proportion in %; sd: standard deviation in %; p-value: two-sided Fishers’ p value
- aIn total, 217 subject-genotype combinations were found in the 95 HPV positive subjects. Their distribution is shown in fig. 1
- bFour subjects were infected by a single vaccine genotype. Five were infected by a single vaccine genotype and by at least another non vaccine genotype
